Malaysia vs Namibia: Average cost of drugs for extensively drug-resistant tuberculosis
Malaysia
10,000 constant 2022 US$
in 2024
Namibia
13,642 constant 2022 US$
in 2024
Malaysia rank
4th
Namibia rank
2nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Malaysia
- Namibia
How they compare
Namibia currently reports 13,642 constant 2022 US$ against 10,000 constant 2022 US$ in Malaysia, a difference of 3,642 constant 2022 US$.
That makes Namibia's figure about 1.4 times Malaysia's.
The two have swapped places 1 time across 6 shared years of data; in 2019 it was Malaysia ahead.
Malaysia ranks 4th and Namibia ranks 2nd of 56 countries.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malaysia | Namibia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 45,000 constant 2022 US$ | 25,350 constant 2022 US$ | 19,650 constant 2022 US$ | Malaysia |
| 2020s | 22,000 constant 2022 US$ | 18,909 constant 2022 US$ | 3,091 constant 2022 US$ | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Malaysia or Namibia?
- Namibia, at 13,642 constant 2022 US$ against 10,000 constant 2022 US$ in Malaysia as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Malaysia and Namibia?
- 3,642 constant 2022 US$, with Namibia ahead.
- How many years of comparable data are there for Malaysia and Namibia?
- 6 years are reported by both, from 2019 to 2024.
- How do Malaysia and Namibia rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Malaysia ranks 4th and Namibia ranks 2nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.